pharma · Colorectal Cancer · Lymphoma, Extranodal NK-T-Cell
Samsung Bioepis
Samsung Bioepis NL B.V.
Samsung Bioepis is a pharma organization headquartered in KR. Primary therapeutic focus areas include Colorectal Cancer, Lymphoma, Extranodal NK-T-Cell, Cancer of Stomach, Dyspepsia, Depression. NovaPharmaNews links 24 c
Yeonsu-gu, Incheon 21987, KR HQ
2012 Founded
1,589 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- Yeonsu-gu, Incheon 21987, KR
- Founded
- 2012
- Employees
- 1,589
- Programs
- 24
- Drugs
- 34
- Patents
- 0
doxazosin plus tolterodine SR
Approved · small molecule · Overactive Bladder
doxazosin plus tolterodine SR for Overactive Bladder is a Approved program (small_molecule) at Samsung Bioepis NL B.V. with 1 ClinicalTrials.gov record(s).
Internal code 2008-08-092
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Samsung Bioepis NL B.V.
- Phase
- Approved
- Modality
- small_molecule
- Indication
- Overactive Bladder
- Status
- completed
- Trials
- 1